Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

@article{Freedman2011BenefitriskAF,
  title={Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.},
  author={Andrew Nathan Freedman and Binbing Yu and Mitchell H. Gail and J. P. Costantino and Barry I. Graubard and Victor G. Vogel and Garnet L. Anderson and Worta J. McCaskill-Stevens},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 17},
  pages={2327-33}
}
PURPOSE The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically significant higher risk of noninvasive breast cancer. There is a need to summarize the risks and benefits of these agents. PATIENTS AND METHODS Baseline incidence rates of IBC and other health outcomes… CONTINUE READING